Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
24.09.2001 to 06.09.2002
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference Type:
study report
Report date:

Materials and methods

Test guideline
equivalent or similar to guideline
OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
Principles of method if other than guideline:
Modified OECD 422 and USEPA Health Effects test guideline OPPTS 870.3650 (2000)
GLP compliance:
yes (incl. QA statement)
Limit test:

Test material

Constituent 1
Chemical structure
Reference substance name:
EC Number:
EC Name:
Cas Number:
Molecular formula:

Test animals

Details on test animals or test system and environmental conditions:
- Source: Charles River Laboratories, Inc.
- Age at study initiation: At least 8 weeks
- Weight at study initiation: Males: 253-301 g; Females: 181-229 g
- Fasting period before study: None
- Housing: Individually housed in suspended wire-mesh cages. Pregnant females were moved into shoebox cages no later than three days prior to their expected delivery date
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: Five days

- Temperature (°C): 19-25
- Humidity (%): 30-70
- Air changes (per hr): 10-15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 01.10.2001 To: 11.04.2002

Administration / exposure

Route of administration:
oral: gavage
corn oil
Details on oral exposure:
PREPARATION OF DOSING SOLUTIONS: The dosing formulations were prepared daily by adding an appropriate amount of test substance to a measured amount of vehicle (dried and de-acidified) under nitrogen atmosphere.

- Justification for use and choice of vehicle (if other than water): Corn oil was dried and de-acidified to removal residual water before use as test substance hydrolyses in contact with moisture.
- Lot/batch no. (if required): 070K0127
- Purity: 100 %
Analytical verification of doses or concentrations:
Details on analytical verification of doses or concentrations:
Concentration, homogeneity and stability of the test substance in the vehicle were verified by gas chromatopgraphy with a flame ionisation detection (FID). Concentration verification was conducted on a weekly basis.
Duration of treatment / exposure:
Males: 28 days (beginning 2 weeks prior to mating)
Toxicity phase female: 29 days (beginning 2 week prior to mating)
Reproductive phase females: 39-44 days (2 weeks prior to mating, throughout mating and pregnancy until day 3 postpartum
Frequency of treatment:
Daily (seven days/week)
Doses / concentrationsopen allclose all
Dose / conc.:
25 mg/kg bw/day (actual dose received)
Dose / conc.:
125 mg/kg bw/day (actual dose received)
Dose / conc.:
500 mg/kg bw/day (actual dose received)
No. of animals per sex per dose:
10/sex/dose (with an females used for toxicity and reproductive phase groups only)
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: Based on a range-finding study (Dow Corning Corporation, 2002a; study number 9618)
- Rationale for selecting satellite groups: Toxicity phase females used to assess effects in females without the influence of pregnancy, so help investigate whether pregnant animals might be more susceptible to toxicity.
- Post-exposure recovery period in satellite groups: No post-exposure recovery group


Observations and examinations performed and frequency:
- Time schedule: Twice daily for morbidity, moribundity and mortality. General clinical observations were made at least once per day, approximately one hour after dosing.

- Time schedule: Once before the first dosing and weekly thereafter.

- Time schedule for examinations: Individual body weights were recorded weekly beginning approximately one week prior to test substance administration, on the first day of dosing and just prior to scheduled necropsy.

FOOD CONSUMPTION: Individual food consumption was recorded weekly for female animals in the toxicity group for four weeks. Individual food consumption for the male animals and the reproductive group females were recorded during the first two weeks of treatment. Food consumption was not measured during the cohabitation period. Food consumption was measured for the reproductive group females throughout gestation until terminal sacrifice.

- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No



- Time schedule for collection of blood: On the day of scheduled sacrifice
- Anaesthetic used for blood collection: Yes, ketamine HCl/Xylazine
- Animals fasted: Yes, overnight
- How many animals: All male and toxicity group females
- Parameters checked in table 1 were examined.

- Time schedule for collection of blood: On the day of scheduled sacrifice
- Animals fasted: Yes
- How many animals: All male and toxicity group females
- Parameters checked in table 1 were examined.


- Time schedule for examinations: Prior to the start of dosing and during the fourth week of the treatment. The assessments were conducted following the daily dose administration.
- Dose groups that were examined: All male and toxicity group females.
- Battery of functions tested: cageside observations, hand-held observations, open field observations, categorical observations, measurements/counts, motor activity.

Sacrifice and pathology:
GROSS PATHOLOGY: Yes (see table 2). Males and toxicity group females were subjected to a complete gross necropsy that included examination of the cranial, thoracic and abdominal cavities and their contents.
HISTOPATHOLOGY: Yes (see table 2). A thorough histopathological examination was performed on the tissues collected for the control and high dose male and female toxicity group animals.
Other examinations:
See Section 7.8 for examinations relating to reproductive and developmental toxicity.
All data analysis was carried out using SAS. In all comparisons, the family wise error rate was held at 5% (alpha=0.05). Prior to this analysis, an exploratory analysis was carried out on all variables tested. Bartlett's test was used to check for heterogeneity of variances and a Kolmogorov-Smirnov test was used to test normality of the data. Parametric data was then tested using one-way Analysis of Variance (ANOVA) followed by Dunnett's Test (if significant). Non-parametric data were tested by Kruskal Wallis Test followed by Wilcoxon (if significant). For variables that had multiple measurements across time Repeated Measurement ANOVA was used to analyse the data. Categorical data were tested for equal proportions using the Fisher's Exact Test.

Statistically significant probabilities are reported at either the p≤0.05 or p≤0.01 levels.

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
mortality observed, treatment-related
Body weight and weight changes:
no effects observed
Food consumption and compound intake (if feeding study):
no effects observed
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Clinical biochemistry findings:
no effects observed
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
no effects observed
Histopathological findings: neoplastic:
not examined
Details on results:
CLINICAL SIGNS AND MORTALITY: One male in the 125 mg/kg bw/day dose group was found dead on study day 17 due to renal disease unrelated to treatment. There were two females in the reproductive groups that died due to dosing errors. All other animals survived to scheduled sacrifice. Clear perioral soiling was slightly more common in the high dose group. In the high dose groups there were increased nasal sounds, laboured breathing and/or soft squeaky vocalisation for one male and four toxicity and five reproductive group females. At 125 mg/kg bw/day, one toxicity group and one reproductive group female had increased nasal sounds. At 25 mg/kg bw/day, one toxicity group female exhibited soft squeaky vocalisation for three days of the study. The incidence of nasal sounds/squeaky vocalisation was noted in some animals and several times in others to a maximum of 18 days during the study. These findings were not observed in control rats.

BODY WEIGHT AND WEIGHT GAIN: Mean body weights in males and females in the 25, 125 and 500 mg/kg bw/day groups were comparable to the control group values throughout the study; no statistically significant differences were noted. Reductions (not statistically significant) in weekly body weight gain were observed in the 25 and 125 mg/kg bw/day group males during week 4. These reductions were not considered to be test substance-related since the difference did not occur in a dose-dependent manner and no reductions were noted in female body weight gains during this time period.

FOOD CONSUMPTION: There were no statistically significant differences in food consumption in any group.

HAEMATOLOGY: There were no treatment-related effects on haematology parameters. However, in the toxicity group females there was a statistically-significant increase in platelet counts compared to controls. The counts for the treated groups were within published historical control ranges, whereas controls in the present study were somewhat below those ranges. No biological/toxicological significance is attributed to treatment.

CLINICAL CHEMISTRY: There were no treatment-related effects on clinical chemistry. However, in females, there was a statistically significant decrease in the chloride value (1.9%) in the high dose group, and a slight decrease (1.4%) in sodium in the middle and high dose groups. There was no dose-response. Sodium values for all female groups, including controls, were within or slightly below published historical control ranges. Chloride values for all groups were slightly above published control ranges. There were no associated clinical or morphological findings, so the findings were not thought to be biologically or toxicologically significant.

FOB: Cage side observations: There were no treatment-related changes noted in unusual body movements, abnormal behaviour, posture or resistance to removal.
Handling observations: Palpebral closure, lacrimation, pupil size and reactivity, salivation, muscle tone, extensor thrust response and reactivity to handling were not affected by the treatment.
Open Field Observations: No differences were apparent between the control and treated groups in the open field observations.
Categorical Observations: No differences between control and treated groups when skin or hair coat, behaviour, respiration, muscle movements, eyes, urine or faeces, soiling, posture or general abnormalities were evaluated.
Measurements/counts: There was no effect on rectal temperature, hindlimb grip strength or landing foot splay assessments.
Motor activity: There were no effects on motor activity.

ORGAN WEIGHTS: There were no treatment-related effects on organ weights. There was no dose-response associated with a statistically-significant small increase in relative prostate weight in the 25 mg/kg bw/day group.

GROSS PATHOLOGY: There were no findings attributable to the test substance.

HISTOPATHOLOGY: There were no treatment-related findings.

Effect levels

Dose descriptor:
Effect level:
>= 500 mg/kg bw/day (actual dose received)
Based on:
test mat.
Basis for effect level:
other: No treatment-related adverse effects observed.

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

In an oral gavage study conducted to OECD 422 and to GLP (reliability score 1) the NOAEL for repeated dose toxicity was at least 500 mg/kg bw/day for N-(3-(trimethoxysilyl)propyl)ethylenediamine in rats.